Jae-Lyun Lee

20PUBLICATIONS
173CO-AUTHORS
Cancer geneticsPredictive and prognostic markersMolecular targetsPharmaceutical delivery technologiesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Nov 13, 2025
Bevacizumab plus Erlotinib in Advanced Solid Cancers with Krebs Cycle Gene Mutations: A Multicenter Phase II Study (BRISK; KCSG AL22-16).

Hyehyun Jeong, Changhoon Yoo, Shinkyo Yoon

|Oct 17, 2024
Early stage adrenocortical carcinoma-what contributes to poor prognosis after adrenalectomy? A retrospective cohort study.

Douk Kwon, Cheong-Sil Rah, Byung-Chang Kim

|Jan 10, 2024
IFITM3-mediated activation of TRAF6/MAPK/AP-1 pathways induces acquired TKI resistance in clear cell renal cell carcinoma.

Se Un Jeong, Ja-Min Park, Sun Young Yoon

|Oct 20, 2023
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.

William K Kelly, Daniel C Danila, Chia-Chi Lin

|Oct 20, 2023
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.

Olivier Nolan-Stevaux, Cong Li, Lingming Liang

|Aug 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).

Alexandra Drakaki, Thomas Powles, Aristotelis Bamias

Pageof 4

Frequent Collaborators

3 joint publications

Howard Gurney

3 joint publications

Rustem Airatovich Gafanov

3 joint publications

Inkeun Park

2 joint publications

Hee Sang Hwang